Linking Gba1 E326K mutation to microglia activation and mild age-dependent dopaminergic Neurodegeneration

Abstract

Mutations in the GBA1 gene have been identified as a prevalent genetic risk factor for Parkinsons disease (PD). GBA1 mutations impair enzymatic activity, leading to lysosomal dysfunction and elevated levels of -synuclein (-syn). While most research has primarily focused on GBA1s role in promoting synucleinopathy, emerging evidence suggests that neuroinflammation may be a key pathogenic alteration caused by GBA1 deficiency. To examine the molecular mechanism underlying GBA1 deficiency-mediated neuroinflammation, we generated Gba1 E326K knock-in (KI) mice using the CRISPR/Cas9 technology, which is linked to an increased risk of PD and dementia with Lewy bodies (DLB). In the ventral midbrain and hippocampus of 24-month-old Gba1 E326K KI mice, we found a moderate decline in GBA1 enzymatic activity, a buildup of glucosylceramide, and an increase in microglia density. Furthermore, we observed increased levels of pro-inflammatory cytokines and formation of reactive astrocytes in primary microglia and astrocytes, respectively, cultured from Gba1 E326K KI mice following treatment with pathologic -syn preformed fibrils (PFF). Additionally, the gut inoculation of -syn PFF in Gba1 E326K KI mice significantly enhanced the accumulation of Lewy bodies in the dentate gyrus of the hippocampus, accompanied by aggravated neuroinflammation and exacerbated non-motor symptoms. This research significantly enhances our understanding of the Gba1 E326K mutations involvement in neuroinflammation and the cell-to-cell transmission of pathogenic -syn in the brain, thereby opening new therapeutic avenues.